IFP Advisors’s Autolus Therapeutics AUTL Stock Holding History

IFP Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-50	Closed	-$2K	–	2422
2018 Q4	$2K	Buy	+50	New	+$1.65K	﹤0.01%	3121

Other funds holding AUTL

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

IFP Advisors's AUTL Position: Q1 2019 in Review

IFP Advisors sold out of Autolus Therapeutics (AUTL) in Q1 2019, closing a stake of 50 shares — an estimated $2K sold.

IFP Advisors first reported a position in AUTL in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 35 funds tracked by Wall St. Rank hold AUTL as of Q1 2019.

IFP Advisors reported no remaining Autolus Therapeutics position as of Q1 2019 after selling out during the quarter.
IFP Advisors sold 50 Autolus Therapeutics shares in Q1 2019, an estimated $2K.
IFP Advisors first reported a position in Autolus Therapeutics in Q4 2018 and held it in 1 quarter.
IFP Advisors's Autolus Therapeutics position peaked at $2K in Q4 2018.
35 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.